Constellation Pharmaceuticals, which is developing epigenetic drugs to address cancer-related gene abnormalities, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The Cambridge, MA-based company was founded in 2008 and plans to list on the Nasdaq under the symbol CNST. J.P. Morgan, Jefferies and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
